Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 102

1.

miR-520g and miR-520h overcome bortezomib resistance in multiple myeloma via suppressing APE1.

Yuan X, Ma R, Yang S, Jiang L, Wang Z, Zhu Z, Li H.

Cell Cycle. 2019 Jul;18(14):1660-1669. doi: 10.1080/15384101.2019.1632138. Epub 2019 Jun 20.

PMID:
31204563
2.

MicroRNA-520g confers drug resistance by regulating p21 expression in colorectal cancer.

Zhang Y, Geng L, Talmon G, Wang J.

J Biol Chem. 2015 Mar 6;290(10):6215-25. doi: 10.1074/jbc.M114.620252. Epub 2015 Jan 23.

3.

Replacement of miR-155 Elicits Tumor Suppressive Activity and Antagonizes Bortezomib Resistance in Multiple Myeloma.

Amodio N, Gallo Cantafio ME, Botta C, Agosti V, Federico C, Caracciolo D, Ronchetti D, Rossi M, Driessen C, Neri A, Tagliaferri P, Tassone P.

Cancers (Basel). 2019 Feb 18;11(2). pii: E236. doi: 10.3390/cancers11020236.

4.

Escape from hsa-miR-519c enables drug-resistant cells to maintain high expression of ABCG2.

To KK, Robey RW, Knutsen T, Zhan Z, Ried T, Bates SE.

Mol Cancer Ther. 2009 Oct;8(10):2959-68. doi: 10.1158/1535-7163.MCT-09-0292.

5.

hsa-miR-631 resensitizes bortezomib-resistant multiple myeloma cell lines by inhibiting UbcH10.

Xi H, Li L, Du J, An R, Fan R, Lu J, Wu YX, Wu SX, Hou J, Zhao LM.

Oncol Rep. 2017 Feb;37(2):961-968. doi: 10.3892/or.2016.5318. Epub 2016 Dec 14.

PMID:
28000886
6.

Inhibition of thioredoxin activates mitophagy and overcomes adaptive bortezomib resistance in multiple myeloma.

Zheng Z, Fan S, Zheng J, Huang W, Gasparetto C, Chao NJ, Hu J, Kang Y.

J Hematol Oncol. 2018 Feb 27;11(1):29. doi: 10.1186/s13045-018-0575-7.

7.

Sensitization of Gastric Cancer Cells to 5-FU by MicroRNA-204 Through Targeting the TGFBR2-Mediated Epithelial to Mesenchymal Transition.

Li LQ, Pan D, Chen Q, Zhang SW, Xie DY, Zheng XL, Chen H.

Cell Physiol Biochem. 2018;47(4):1533-1545. doi: 10.1159/000490871. Epub 2018 Jun 21.

8.

MicroRNA-520g promotes epithelial ovarian cancer progression and chemoresistance via DAPK2 repression.

Zhang J, Liu L, Sun Y, Xiang J, Zhou D, Wang L, Xu H, Yang X, Du N, Zhang M, Yan Q, Xi X.

Oncotarget. 2016 May 3;7(18):26516-34. doi: 10.18632/oncotarget.8530.

9.

MiR-7-5p-mediated downregulation of PARP1 impacts DNA homologous recombination repair and resistance to doxorubicin in small cell lung cancer.

Lai J, Yang H, Zhu Y, Ruan M, Huang Y, Zhang Q.

BMC Cancer. 2019 Jun 18;19(1):602. doi: 10.1186/s12885-019-5798-7.

10.

miR-520h is crucial for DAPK2 regulation and breast cancer progression.

Su CM, Wang MY, Hong CC, Chen HA, Su YH, Wu CH, Huang MT, Chang YW, Jiang SS, Sung SY, Chang JY, Chen LT, Chen PS, Su JL.

Oncogene. 2016 Mar 3;35(9):1134-42. doi: 10.1038/onc.2015.168. Epub 2015 May 18. Erratum in: Oncogene. 2017 Aug 21;:.

PMID:
25982274
11.

Epigenetic silencing of miR-137 induces drug resistance and chromosomal instability by targeting AURKA in multiple myeloma.

Qin Y, Zhang S, Deng S, An G, Qin X, Li F, Xu Y, Hao M, Yang Y, Zhou W, Chang H, Qiu L.

Leukemia. 2017 May;31(5):1123-1135. doi: 10.1038/leu.2016.325. Epub 2016 Nov 18.

PMID:
27857131
12.

MiR-29b replacement inhibits proteasomes and disrupts aggresome+autophagosome formation to enhance the antimyeloma benefit of bortezomib.

Jagannathan S, Vad N, Vallabhapurapu S, Vallabhapurapu S, Anderson KC, Driscoll JJ.

Leukemia. 2015 Mar;29(3):727-38. doi: 10.1038/leu.2014.279. Epub 2014 Sep 19.

13.

Dysregulation of EZH2/miR-138 axis contributes to drug resistance in multiple myeloma by downregulating RBPMS.

Rastgoo N, Pourabdollah M, Abdi J, Reece D, Chang H.

Leukemia. 2018 Nov;32(11):2471-2482. doi: 10.1038/s41375-018-0140-y. Epub 2018 Apr 24.

PMID:
29743723
14.

Differential Expression of MicroRNA-19b Promotes Proliferation of Cancer Stem Cells by Regulating the TSC1/mTOR Signaling Pathway in Multiple Myeloma.

Wang N, Liang X, Yu W, Zhou S, Fang M.

Cell Physiol Biochem. 2018;50(5):1804-1814. doi: 10.1159/000494821. Epub 2018 Nov 5.

15.

XPO1 inhibitor combination therapy with bortezomib or carfilzomib induces nuclear localization of IκBα and overcomes acquired proteasome inhibitor resistance in human multiple myeloma.

Turner JG, Kashyap T, Dawson JL, Gomez J, Bauer AA, Grant S, Dai Y, Shain KH, Meads M, Landesman Y, Sullivan DM.

Oncotarget. 2016 Nov 29;7(48):78896-78909. doi: 10.18632/oncotarget.12969.

16.

Study on the Association Between miRNA-202 Expression and Drug Sensitivity in Multiple Myeloma Cells.

Shen X, Guo Y, Qi J, Shi W, Wu X, Ni H, Ju S.

Pathol Oncol Res. 2016 Jul;22(3):531-9. doi: 10.1007/s12253-015-0035-4. Epub 2015 Dec 21.

PMID:
26689580
17.

Breast cancer resistance protein BCRP/ABCG2 regulatory microRNAs (hsa-miR-328, -519c and -520h) and their differential expression in stem-like ABCG2+ cancer cells.

Li X, Pan YZ, Seigel GM, Hu ZH, Huang M, Yu AM.

Biochem Pharmacol. 2011 Mar 15;81(6):783-92. doi: 10.1016/j.bcp.2010.12.018. Epub 2011 Jan 8.

18.

Knockdown of Long Non-Coding RNA XIST Inhibited Doxorubicin Resistance in Colorectal Cancer by Upregulation of miR-124 and Downregulation of SGK1.

Zhu J, Zhang R, Yang D, Li J, Yan X, Jin K, Li W, Liu X, Zhao J, Shang W, Yu T.

Cell Physiol Biochem. 2018;51(1):113-128. doi: 10.1159/000495168. Epub 2018 Nov 15.

19.

Involvement of microRNA-141-3p in 5-fluorouracil and oxaliplatin chemo-resistance in esophageal cancer cells via regulation of PTEN.

Jin YY, Chen QJ, Xu K, Ren HT, Bao X, Ma YN, Wei Y, Ma HB.

Mol Cell Biochem. 2016 Nov;422(1-2):161-170. Epub 2016 Sep 19.

PMID:
27644195
20.

miR-200bc/429 cluster modulates multidrug resistance of human cancer cell lines by targeting BCL2 and XIAP.

Zhu W, Xu H, Zhu D, Zhi H, Wang T, Wang J, Jiang B, Shu Y, Liu P.

Cancer Chemother Pharmacol. 2012 Mar;69(3):723-31. doi: 10.1007/s00280-011-1752-3. Epub 2011 Oct 13.

PMID:
21993663

Supplemental Content

Support Center